KRRO logo

KRRO Korro Bio, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$12.19
-0.25 (-2.01%)

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Market Cap: $167.32Mwww.korrobio.com

Price

No data yet.

Social Signal Score

56
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
63
4 mentions
—
90d
60
5 mentions
—
news: 5

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 2Sell 0Strong Sell 0
Avg price target$15+23.1%
Low $15Median $15High $15
Current Consensus

Revenue

$0.00-100.00%
$0.00$8.08M$16.16M$24.24M
Sep 2019Sep 2026

Analyst Estimates

FY2025
$-9.03
$-9.53–$-8.45
7 analysts
FY2026
$-4.88
$-5.13–$-4.67
8 analysts
FY2027
$-4.80
$-5.52–$-3.69
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ram Aiyar
Sector
Healthcare
Industry
Biotechnology
Employees
58
Beta
2.36
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-3.35
www.korrobio.com